0JQ2 logo

KALA BIO LSE:0JQ2 Stock Report

Last Price

US$6.84

Market Cap

US$32.2m

7D

-3.0%

1Y

-1.6%

Updated

04 Nov, 2024

Data

Company Financials +

0JQ2 Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.

0JQ2 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KALA BIO, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for KALA BIO
Historical stock prices
Current Share PriceUS$6.84
52 Week HighUS$9.00
52 Week LowUS$4.47
Beta-2.13
11 Month Change26.67%
3 Month Change9.44%
1 Year Change-1.58%
33 Year Change-93.49%
5 Year Changen/a
Change since IPO-99.09%

Recent News & Updates

Recent updates

Shareholder Returns

0JQ2GB BiotechsGB Market
7D-3.0%-0.3%-1.3%
1Y-1.6%-14.6%8.9%

Return vs Industry: 0JQ2 exceeded the UK Biotechs industry which returned -14.6% over the past year.

Return vs Market: 0JQ2 underperformed the UK Market which returned 8.9% over the past year.

Price Volatility

Is 0JQ2's price volatile compared to industry and market?
0JQ2 volatility
0JQ2 Average Weekly Movement10.3%
Biotechs Industry Average Movement8.3%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0JQ2's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JQ2's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200943Mark Iwickiwww.kalarx.com

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.

KALA BIO, Inc. Fundamentals Summary

How do KALA BIO's earnings and revenue compare to its market cap?
0JQ2 fundamental statistics
Market capUS$32.21m
Earnings (TTM)-US$38.72m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JQ2 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$38.72m
Earnings-US$38.72m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-8.40
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio253.8%

How did 0JQ2 perform over the long term?

See historical performance and comparison